Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF
Pro members get actionable news alerts up to 30 minutes before other traders — Get our lowest prices
get now
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF
Pro members get actionable news alerts up to 30 minutes before other traders — Get our lowest prices
get now
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Hepatitis C
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy
Gilead Defends Hepatitis C Treatments On Reports Of Side Effects
Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy
Gilead Defends Hepatitis C Treatments On Reports Of Side Effects
Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings
Here's Why Regulus Therapeutics Gained 20%
Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings
Here's Why Regulus Therapeutics Gained 20%
Merck Confirms FDA Approval Of Hep C Drug At A Cost Of $54,600 Per Patient
High Drug Prices Put Gilead Under Fire From Senate Committee
Read More...
Hepatitis C Recent News
Pamela Anderson And Hepatitis C: Which Drug Makers Are Working On A Cure?
Why Johnson & Johnson's Strong Pharmaceutical Business Is A Concern
Health Care And Biotech Sector Looking Sick
CNBC's Meg Tirrell Breaks Down The AbbVie/Express Scripts Deal
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline
Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech Stocks
Takeover Whispers Add To Achillion Pharmaceuticals' Momentum
Hepatitis C Stocks Move After Idenix Rockets Up 235%
How Did Analysts Get Gilead's Earnings Completely Wrong?
Market Wrap For January 8: Fed Minutes Released
Possible Hepatitis C Outbreak Could Lift This ETF